Drug Type Small molecule drug |
Synonyms RP-0217 |
Target |
Action inhibitors |
Mechanism PP2A inhibitors(Protein phosphatase 2A inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Asthma | Preclinical | United Kingdom | 01 Jan 2024 | |
| Colitis, Ulcerative | Preclinical | United Kingdom | 01 Jan 2024 | |
| Crohn Disease | Preclinical | United Kingdom | 01 Jan 2024 | |
| Inflammation | Preclinical | United Kingdom | 01 Jan 2024 | |
| Pulmonary Disease, Chronic Obstructive | Preclinical | United Kingdom | 01 Jan 2024 | |
| Rhinitis | Preclinical | United Kingdom | 01 Jan 2024 |





